Clinical Trial Update: Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection [Phase 1, Phase 2]

View source ↗

Summary

NWRD09 is being evaluated in Phase 1/Phase 2 for female participants with persistent HPV16 infection, and the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• NWRD09

Snippet

Sponsor: Newish Biotech (Wuxi) Co., Ltd. | Conditions: Persistent HPV16 Infection | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING